News

Zydus and Pharm Aid Ltd., enter into an exclusive agreement for vaccine technology in Russia

 September 19, 2017

Cadila Healthcare Limited (Zydus Cadila), an innovation-driven global healthcare company has entered into an exclusive agreement for the technology know-how for varicella vaccine production in the Russian Federation with Pharm Aid Ltd., headquartered in Russia. The exclusive agreement was signed at the BIOTECHMED conference in Gelendzhik, Russia. Pharm Aid Ltd, has been set up by Nacimbio together with Ishvan Pharmaceuticals Ltd., for the localization of innovative vaccine production in Russia.

Through this agreement, Zydus gains access to the public and private market segments in the Russian Federation, Belarus, Uzbekistan, Kazakhstan, Armenia and Kyrgyzstan. With an absence of assured supply of indigenously manufactured varicella vaccine, this vaccine does not feature currently in the National Immunisation Programme. The agreement aims to bring in a continuous supply of vaccines which could be included in the critical childhood immunization programme. The demand is estimated at 3 million doses per annum in the Russian Federation alone.

Sources: Rostec, Cadila Healthcare Limited

 

 

Zydus Cadila enters into agreement with Sarvac Limited to scout for partners to market its vaccines in Russia and CIS

 April 07, 2015

 Zydus Cadila, a leading global healthcare company headquartered in Ahmedabad, India has entered into a contract with a consulting company, Sarvac Limited to look for partners to market its vaccines in Russia and CIS. This is in line with the group’s mission of reaching out with innovative therapies to bridge unmet healthcare needs, globally. 

 The group is seeking a partner to co-market its vaccines in Russia and CIS. With this, Zydus aims to become one of the leading vaccine providers in not only India but also worldwide including the BRICs.

 Zydus Cadila’s initiatives in the research and manufacture of vaccines is spearheaded by its Vaccine Technology Centre (VTC). VTC has two state-of-the-art R & D Centres, one located in in Catania, Italy and the other in Ahmedabad. The group has indigenously developed, manufactured and was the first to launch India’s first vaccine against H1N1 (Vaxiflu-S) in 2010. VTC’s Rabies Vaccine Manufacturing facility has received WHO pre-qualification, and is one of the largest Rabies manufacturing facility in India.

 

About Zydus Cadila

Headquartered in Ahmedabad, India, Zydus Cadila is an innovative, global pharmaceutical company that discovers, manufactures and markets a broad range of healthcare therapies. The group employs over 16,500 people worldwide. As a leading healthcare provider, it aims to become a global research based pharmaceutical company by 2020. The group has a strong research pipeline of NCEs, biologics and vaccines and has over 1200 scientists engaged in R & D and is dedicated to creating healthier communities globally.

 

About Sarvac Limited

The consulting company Sarvac Limited has long recognized experience in vaccines promotion and partners search for vaccine technology transfer. In 2012, Sarvac Limited successfully found a Russian partner for the Dutch manufacturer of inactivated polio vaccine localization (fill & finish). At present, the company works on projects of partners search for monoclonal antibodies, vaccine production equipment and travel vaccine localization.